financetom
Business
financetom
/
Business
/
Travel booking platform Klook reveals robust revenue growth in US IPO filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel booking platform Klook reveals robust revenue growth in US IPO filing
Nov 10, 2025 9:59 AM

Nov 10 (Reuters) - SoftBank-backed Klook reported a

24.4% jump in revenue in 2024, the online travel booking

platform said in its filing for a U.S. initial public offering

on Monday, signaling steady investor demand even as the

government remains shut.

The U.S. IPO market has rebounded from tariff-driven

volatilities, as a rally in equities and interest rate cuts

boosted investor demand for fresh offerings, though a prolonged

government shutdown has caused some delays.

Klook's offering followed recent debuts by molecular

diagnostics firm BillionToOne ( BLLN ) and another Apollo-backed

company Grupo Aeromexico, earlier this month.

The Hong Kong-based company reported revenue of $417.1

million in 2024, compared with $335.2 million a year earlier.

Its IPO filing comes at a time when the global tourism

industry is experiencing rapid growth following the COVID-19

pandemic, driven by a surge in consumer spending.

The travel sector's contribution to global GDP is projected

to reach $11.7 trillion in 2025, 10.3% of global GDP, according

to a May report by the World Travel and Tourism Council.

Founded in 2014, Klook offers bookings for tours,

attractions, transport and other travel experiences across a

wide range of locations globally.

It competes with global platforms such as Booking.com,

TripAdvisor, China's Trip.com and South Korea's Yanolja.

In February, Klook raised $100 million in a funding round

led by European investment firm Vitruvian Partners, though it

did not disclose its valuation at the time.

Klook aims to list on the New York Stock Exchange under the

symbol "KLK".

Goldman Sachs, Morgan Stanley and J.P. Morgan are among the

lead underwriters for the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved